Answers are grounded in this paper and cite their sources.
LOLA benefited patients with overt hepatic encephalopathy (I or II), whereas these data do not support the use of LOLA for patients with subclinical hepatic encephalopathy.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: